{
    "nctId": "NCT03099031",
    "briefTitle": "Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)",
    "officialTitle": "Prediction of Thromboembolic Recurrences in Cancer Patients With Venous Thromboembolic Disease (TED)",
    "overallStatus": "COMPLETED",
    "conditions": "Venous Thromboembolism",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 420,
    "primaryOutcomeMeasure": "Venous thromboembolism recurrence",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Cancer patients with histologically confirmed, active or evolving, solid or liquid tumour, or\n* Suspected malignant tumour confirmed within a month of index VTE occurrence\n* Treated with specific metastatic or adjuvant anti-cancer treatment\n* Patients with recent diagnosis of documented symptomatic or incidental VTE and a prescription of tinzaparin for 6 months\n* Proximal or distal VTE of lower limbs\n* Pulmonary embolism\n* Inferior or superior vena cava thrombosis\n* Iliac vein thrombosis\n\nExclusion Criteria:\n\n* Skin cancer other than melanoma\n* Life expectancy less than 6 months\n* Superficial isolated thrombosis\n* Isolated subsegmental pulmonary embolism\n* Cerebral, visceral thrombosis\n* Superior limbs VTE or Central catheter thrombosis\n* Patients being treated with anticoagulants by more than 7 days",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}